Home › Funds › Elmind Capital, LP › AMLX
Elmind Capital, LP position in AMLX
AMYLYX PHARMACEUTICALS INC · Health Care
Elmind Capital, LP reported holding 894,760 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$26.0M, representing 6.45% of its reported portfolio and ranking #6 among its reported holdings. Elmind Capital, LP has disclosed AMLX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Elmind Capital, LP's AMLX position evolved
Elmind Capital, LP first disclosed a stake in AMLX in Q4 2025 at 112,000 shares (US$1.4M). The position peaked in Q3 2026 at 894,760 shares, worth US$26.0M. Across 4 filings, Elmind Capital, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 894,760 shares valued at US$26.0M — an increase of 782,760 shares quarter over quarter.. Notable position changes include a 699% increase in Q3 2026 (shares fell 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 112.00K | $1.35M | New |
| Q1 2026 | 112.00K | $1.56M | Hold |
| Q2 2026 | 112.00K | $2.01M | Hold |
| Q3 2026 | 894.76K | $26.04M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AMLX and 13F data
AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 53 other funds we track also report a position in AMLX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$307.7M), TCG Crossover Management, LLC (US$181.7M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$158.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AMLX
- PERCEPTIVE ADVISORS LLC 10.57M sh · $307.70M · Q3 2026
- TCG Crossover Management, LLC 6.24M sh · $181.69M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 5.43M sh · $157.97M · Q3 2026
- Saturn V Capital Management LP 4.47M sh · $130.12M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 4.28M sh · $124.53M · Q3 2026
- First Light Asset Management, LLC 3.99M sh · $116.01M · Q3 2026
- Siren, L.L.C. 2.48M sh · $72.19M · Q3 2026
- Commodore Capital LP 2.00M sh · $58.20M · Q3 2026
- Boxer Capital Management, LLC 893.15K sh · $25.99M · Q3 2026
- Rock Springs Capital Management LP 756.77K sh · $22.02M · Q3 2026
- GREAT POINT PARTNERS LLC 700.00K sh · $20.37M · Q3 2026
- Parkman Healthcare Partners LLC 675.10K sh · $19.65M · Q3 2026
More on Elmind Capital, LP
FAQ
How long has Elmind Capital, LP held AMLX?
Elmind Capital, LP has disclosed AMLX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Elmind Capital, LP's current position in AMLX?
As of Q3 2026, Elmind Capital, LP holds 894.76K shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $26.04M, representing 6.45% of its reported portfolio and ranking #6.
Has Elmind Capital, LP been buying or selling AMLX?
In the latest 13F filing (Q3 2026), Elmind Capital, LP increased its position in AMLX. The position peaked in Q3 2026 at 894.76K shares.
Which other funds hold AMLX?
Other major institutional holders of AMLX include PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.